Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Eris Lifesciences Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eris Lifesciences Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Income from Continuing Operations
â‚ą3.9B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
â‚ą55.7B
CAGR 3-Years
47%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
â‚ą44.9B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
â‚ą111.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Income from Continuing Operations
â‚ą19.4B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
186.9B INR
Industry
Pharmaceuticals

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
3.9B INR

Based on the financial report for Jun 30, 2024, Eris Lifesciences Ltd's Income from Continuing Operations amounts to 3.9B INR.

What is Eris Lifesciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
5%

Over the last year, the Income from Continuing Operations growth was 5%. The average annual Income from Continuing Operations growth rates for Eris Lifesciences Ltd have been 2% over the past three years , 5% over the past five years .

Back to Top